LBA15 Primary outcome of the phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer

• DOI: 10.1016/j.annonc.2021.08.2088
• Publication Date: 2021-09-21T22:24:47Z
• Authors: C. Saura Manich; J. O'Shaughnessy; P.G. Aftimos; E. van den Tweel; M. Oesterholt; S.I. Escrivá-de-R...; N. Quenel Tueux; T.J. Tan; J.S. Lim; S. Ladoire; A. Armstrong; T. Crook; A. Stradella; G. Bianchi; R. Mulder; N. Koper; N. Turner
• Keywords: 03 medical and health sciences; 0302 clinical medicine